Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis

OBJECTIVE: Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA). This study was undertaken to analyze changes in lymphocyte cell subsets during baricitinib treatment and to correlate these changes with clinical out...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arthritis Rheumatol
Asıl Yazarlar: Tanaka, Yoshiya, McInnes, Iain B., Taylor, Peter C., Byers, Nicole L., Chen, Lei, de Bono, Stephanie, Issa, Maher, Macias, William L., Rogai, Veronica, Rooney, Terence P., Schlichting, Douglas E., Zuckerman, Steven H., Emery, Paul
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Rheumatoid Arthritis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587754/
https://ncbi.nlm.nih.gov/pubmed/30058112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40680
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller